The most common treatment for prostate cancer depends heavily on how advanced the cancer is, but for the majority of men diagnosed today, active surveillance is the most frequently recommended approach. Because most prostate cancers are caught early and grow slowly, more than half of men with low-risk disease now avoid immediate treatment altogether. For cancers that do require intervention, surgery and radiation therapy are the two primary options, while hormone therapy plays a central role in more advanced cases.
Active Surveillance for Low-Risk Disease
Active surveillance means monitoring the cancer closely without treating it right away. This isn’t ignoring the problem. It involves regular blood tests, imaging, and periodic biopsies to watch for any signs the cancer is becoming more aggressive. If those signs appear, treatment begins. The goal is to avoid the side effects of surgery or radiation for a cancer that may never cause harm during your lifetime.
This approach has become dramatically more common. Among men with low-risk prostate cancer, the share choosing active surveillance rose from about 27% in 2014 to nearly 60% by 2021. That shift reflects growing evidence that many prostate cancers are slow-growing enough that the risks of treatment outweigh the benefits of acting immediately.
You’re generally a good candidate for active surveillance if your cancer is confined to the prostate, your biopsy shows lower-grade cells (a Gleason score of 6 or below), and your PSA density is low. Doctors have been expanding these criteria over time, finding that men with slightly more cancer detected on biopsy can still be safely monitored as long as the grade and PSA density stay within those thresholds. The key factors that do predict trouble are a higher Gleason score (7 or above) and elevated PSA density, so those findings typically push the decision toward active treatment.
Surgery: What to Expect
When treatment is needed for cancer that hasn’t spread beyond the prostate, radical prostatectomy (removing the entire prostate gland) is one of the two main options. Most of these surgeries today are done robotically through several small incisions in the lower abdomen rather than one large open cut. Robotic-assisted surgery has largely replaced the open approach because it results in less blood loss, less pain, and a shorter hospital stay.
Recovery follows a fairly predictable timeline. You’ll typically go home one to two days after surgery. A urinary catheter stays in place for 7 to 14 days. During the first four weeks, you’ll need to avoid lifting anything over 10 pounds and skip activities that involve bending, pulling, pushing, or twisting. Most people return to their usual routine within four to six weeks, though full recovery of urinary and sexual function takes longer.
The trade-off with surgery is a higher short-term risk of side effects compared to radiation. Men who undergo prostatectomy are roughly five times more likely to have urinary leakage issues and about three and a half times more likely to experience erectile dysfunction in the first few years after treatment compared to men who choose radiation. These differences narrow over time and become similar by about 15 years out, but they matter when you’re deciding between the two.
Radiation Therapy as an Alternative
Radiation is the other primary treatment for localized prostate cancer and produces similar long-term survival outcomes to surgery. It works by directing high-energy beams at the prostate to destroy cancer cells. The two main forms are external beam radiation, delivered from a machine outside the body over several weeks of daily sessions, and brachytherapy, which involves placing radioactive seeds directly into the prostate.
Radiation has a gentler side-effect profile in the early years. Urinary incontinence and erectile dysfunction are significantly less common in the short to intermediate term compared to surgery. However, radiation carries its own unique risk: bowel irritation, which can cause rectal discomfort, urgency, or bleeding. Over very long follow-up periods of 15 years, the rates of urinary and sexual side effects between surgery and radiation tend to converge.
For men with intermediate or high-risk localized cancer, radiation is often combined with hormone therapy to improve outcomes. This combination has become standard practice and can mean several months to a few years of hormone-suppressing treatment alongside or after the radiation course.
Hormone Therapy for Advanced Disease
Hormone therapy, also called androgen deprivation therapy (ADT), works by cutting off the testosterone that fuels prostate cancer growth. It’s the backbone of treatment for cancer that has spread beyond the prostate or that has come back after earlier surgery or radiation. It’s also used alongside radiation for higher-risk localized cancers.
The most common form involves injections that stop the brain from signaling the testicles to produce testosterone. These are given on a schedule ranging from monthly to every few months. A newer pill-based option achieves the same effect without injections. The side effects of hormone therapy reflect the loss of testosterone: hot flashes, reduced sex drive, fatigue, loss of muscle mass, weight gain, and over time, weaker bones.
For men diagnosed with cancer that has already spread, ADT alone is no longer considered sufficient. Current standard treatment combines ADT with a second hormone-blocking drug or chemotherapy, which has been shown to extend survival compared to ADT on its own.
When Cancer Stops Responding to Hormones
Some advanced prostate cancers eventually become resistant to standard hormone therapy, a stage called castration-resistant disease. At this point, treatment shifts to more aggressive options. The most common approaches include newer hormone-blocking pills that work through different mechanisms than initial ADT, as well as chemotherapy. The specific choice depends on what treatments were used previously, how symptomatic the cancer is, and how well the patient can tolerate therapy.
How Newer Imaging Is Changing Decisions
A relatively recent development in prostate cancer care is PSMA PET scanning, a type of imaging that detects prostate cancer cells throughout the body with much greater accuracy than older scans. In head-to-head trials, PSMA PET achieved 91% accuracy for detecting cancer spread to lymph nodes, compared to 59% for conventional imaging.
This matters because better imaging changes treatment plans. Across multiple studies, roughly 20% to 50% of patients had their treatment strategy altered after a PSMA PET scan, whether that meant expanding a radiation field, adding hormone therapy, or switching from local treatment to a whole-body approach after discovering previously hidden cancer spread. One analysis of 100 patients found that 73% had their plans changed based on PSMA PET findings, and those who received adjusted treatment had better two-year survival rates.
Survival Rates by Stage
Prostate cancer survival is strongly tied to how far the cancer has spread at diagnosis. For localized disease (confined to the prostate) and regional disease (spread to nearby lymph nodes), the five-year relative survival rate is above 99%. That means men with these stages are essentially just as likely to be alive five years later as men without prostate cancer. For distant disease that has spread to bones or other organs, the five-year survival rate drops to 38%.
These numbers, based on men diagnosed between 2015 and 2021, help explain why active surveillance is so common for early-stage cancers. When survival is already above 99%, the priority shifts from aggressive treatment to preserving quality of life. For advanced cancers, the combination of hormone therapy with newer drugs has been improving outcomes, though distant disease remains the most serious scenario.